Respiratory specialist Vectura (LSE: VEC) says VR475 has met the primary endpoint in its Phase IIb/III trial of investigational drug-device product in severe asthma patients.
It delivers an already-approved corticosteroid, budesonide, to the lungs via the company’s Akita jet inhalation system, which is controlled by a smart card. This is designed to deliver budesonide to the small airways of the lungs more effectively than traditional delivery devices.
The trial investigated the efficacy, safety and tolerability of VR475 in treating oral corticosteroid (OCS)-dependent asthma patients, and compared the effects of two doses of budesonide delivered by Akita with placebo and budesonide delivered by a conventional nebulizer. Both treatments were added to standard severe asthma therapies for 18 weeks.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze